Please wait while the formulary information is being retrieved.
Drug overview for ACTICARNITINE SF (levocarnitine):
Generic name: levocarnitine (lee-voh-KAR-nih-teen)
Drug class: Levocarnitine
Therapeutic class: Electrolyte Balance-Nutritional Products
Levocarnitine is a naturally occurring amino acid derivative essential for mammalian energy metabolism.
No enhanced Uses information available for this drug.
Generic name: levocarnitine (lee-voh-KAR-nih-teen)
Drug class: Levocarnitine
Therapeutic class: Electrolyte Balance-Nutritional Products
Levocarnitine is a naturally occurring amino acid derivative essential for mammalian energy metabolism.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for ACTICARNITINE SF (levocarnitine) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for ACTICARNITINE SF (levocarnitine):
No enhanced Dosing information available for this drug.
Administer levocarnitine orally (as a solution or tablets) or by IV injection or infusion.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ACTICARNITINE SF (levocarnitine):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for ACTICARNITINE SF (levocarnitine):
Drug contraindication overview.
*None.
*None.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Seizure disorder |
The following adverse reaction information is available for ACTICARNITINE SF (levocarnitine):
Adverse reaction overview.
Common adverse effects reported with oral levocarnitine therapy include transient nausea and vomiting, abdominal cramps, diarrhea, and body odor. Common adverse effects reported with IV levocarnitine therapy include transient nausea and vomiting, body odor, and gastritis. Patients on chronic hemodialysis may experience injection site reactions, headache, pain, diarrhea, flu syndrome, pharyngitis, infection, hypertension, vomiting, abdominal pain, hypotension, dizziness, increased cough, chest pain, hypercalcemia, accidental injury, asthenia, nausea, fever, anemia, hypervolemia, paresthesia, rhinitis, or dyspnea.
Seizures were reported in patients, with or without preexisting seizure activity, receiving either oral or IV levocarnitine. Increased seizure frequency and/or severity also has been reported in patients with preexisting seizure activity.
Common adverse effects reported with oral levocarnitine therapy include transient nausea and vomiting, abdominal cramps, diarrhea, and body odor. Common adverse effects reported with IV levocarnitine therapy include transient nausea and vomiting, body odor, and gastritis. Patients on chronic hemodialysis may experience injection site reactions, headache, pain, diarrhea, flu syndrome, pharyngitis, infection, hypertension, vomiting, abdominal pain, hypotension, dizziness, increased cough, chest pain, hypercalcemia, accidental injury, asthenia, nausea, fever, anemia, hypervolemia, paresthesia, rhinitis, or dyspnea.
Seizures were reported in patients, with or without preexisting seizure activity, receiving either oral or IV levocarnitine. Increased seizure frequency and/or severity also has been reported in patients with preexisting seizure activity.
There are 5 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Anaphylaxis Bronchospastic pulmonary disease Laryngeal edema Muscle weakness Seizure disorder |
There are 9 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal pain with cramps Diarrhea Nausea Vomiting |
Body odor Gastritis |
| Rare/Very Rare |
|---|
|
Facial edema Skin rash Urticaria |
The following precautions are available for ACTICARNITINE SF (levocarnitine):
Dosage of levocarnitine in pediatric patients <=18 years of age was based on specific patient case record observations rather than on studies that specifically defined age by protocol.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
There are no adequate and well controlled studies with levocarnitine use in pregnant women. Animal reproduction studies have not shown any evidence of fetal harm. Use during pregnancy only if clearly needed.
Levocarnitine is distributed into milk in cows; it is not known whether the drug is distributed into human milk. Weigh risks and benefits of use in nursing mothers. The manufacturer recommends to consider discontinuance of nursing or the drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for ACTICARNITINE SF (levocarnitine):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ACTICARNITINE SF (levocarnitine)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool